Globally, approximately 139 million people are expected to have Alzheimer's disease (AD) by 2050. Magnetic resonance imaging ...

We have entered a new era of improved and emerging biologically-based diagnostic biomarkers for Alzheimer's disease (AD) and ...

Alzheimer’s disease experts have updated their diagnosis guidelines for the first time in more than 20 years, laying o ...

An expert workgroup representing primary and specialty care has developed new guidelines for comprehensive evaluation of patients who may have cognitive impairment or dementia due to Alzheimer’s ...

Alzheimer’s patients with cognitive decline undergo blood tests, looking at plasma bio-markers. Researchers say it could be a ...

Scientists believe that Alzheimer's disease develops over decades, but it is usually not diagnosed until well after patients have started to experience | Clinical And Molecular Dx ...

The 2024 update to the nation’s roadmap of strategies and actions to address Alzheimer’s disease was released Wednesday by the US Department of Health and Human Services, highlighting federal approval ...

Research from a UMass-Lowell team found that Alzheimer’s patients had certain concentrations of common elements in their ...

Menopause, marked by declining oestrogen, may increase Alzheimer's risk in women. Oestrogen's neuroprotective role diminishes ...

Anavex Life Sciences receives EMA filing acceptance for blarcamesine to review marketing authorization application to treat Alzheimer’s disease: New York Thursday, December 26, ...

Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement. Submission based on favorable ANAVEX ® 2-73-AD-004 ...